Cargando…

Prediction of clinical and biomarker conformed Alzheimer’s disease and mild cognitive impairment from multi-feature brain structural MRI using age-correction from a large independent lifespan sample

Structural neuroimaging has been applied to the identification of individuals with Alzheimer’s disease (AD) and mild cognitive impairment (MCI). However, these methods are greatly impacted by age limiting their utility for detection of preclinical pathology. We built linear models for age based on m...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Binyin, Zhang, Miao, Riphagen, Joost, Morrison Yochim, Kathryn, Li, Biao, Liu, Jun, Salat, David H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476071/
https://www.ncbi.nlm.nih.gov/pubmed/32871388
http://dx.doi.org/10.1016/j.nicl.2020.102387
_version_ 1783579649403518976
author Li, Binyin
Zhang, Miao
Riphagen, Joost
Morrison Yochim, Kathryn
Li, Biao
Liu, Jun
Salat, David H.
author_facet Li, Binyin
Zhang, Miao
Riphagen, Joost
Morrison Yochim, Kathryn
Li, Biao
Liu, Jun
Salat, David H.
author_sort Li, Binyin
collection PubMed
description Structural neuroimaging has been applied to the identification of individuals with Alzheimer’s disease (AD) and mild cognitive impairment (MCI). However, these methods are greatly impacted by age limiting their utility for detection of preclinical pathology. We built linear models for age based on multiple combined structural features using a large independent lifespan sample of 272 healthy adults across a wide age range from the Human Connectome Project Aging study. These models were then used to create a new support vector machine (SVM) training model in 136 CE and 268 control participants based on residues of fit from the expected age-effects relationship. Subsequent validation assessed the accuracy of the SVM model in new datasets. Finally, we applied the classifier to 276 individuals with MCI to evaluate prediction for early impairment and longitudinal cognitive change. The optimal 10-fold cross-validation accuracy was 93.07%, compared to 91.83% without age detrending. In the validation dataset, the classifier for AD obtained an accuracy of 84.85% (56/66), sensitivity of 85.36% (35/41) and specificity of 84% (21/25). Classification accuracy was improved when using the lifespan sample as opposed to the classification sample. Importantly, we observed cross-sectional greater AD specific biomarkers, as well as faster cognitive decline in MCI who were classified as more ‘AD-like’ (MCI-AD), and these effects were pronounced in individuals who were late MCI. The top five contributive features were volumes of left hippocampus, right hippocampus, left amygdala, the thickness of left and right middle temporal & parahippocampus gyrus. Linear detrending for age in SVM for combined structural features resulted in good performance for recognition of AD and AD-specific biomarkers, as well as prediction of MCI progression. Such procedures may be used in future work to enhance prediction in samples with atypical age distributions.
format Online
Article
Text
id pubmed-7476071
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74760712020-09-11 Prediction of clinical and biomarker conformed Alzheimer’s disease and mild cognitive impairment from multi-feature brain structural MRI using age-correction from a large independent lifespan sample Li, Binyin Zhang, Miao Riphagen, Joost Morrison Yochim, Kathryn Li, Biao Liu, Jun Salat, David H. Neuroimage Clin Regular Article Structural neuroimaging has been applied to the identification of individuals with Alzheimer’s disease (AD) and mild cognitive impairment (MCI). However, these methods are greatly impacted by age limiting their utility for detection of preclinical pathology. We built linear models for age based on multiple combined structural features using a large independent lifespan sample of 272 healthy adults across a wide age range from the Human Connectome Project Aging study. These models were then used to create a new support vector machine (SVM) training model in 136 CE and 268 control participants based on residues of fit from the expected age-effects relationship. Subsequent validation assessed the accuracy of the SVM model in new datasets. Finally, we applied the classifier to 276 individuals with MCI to evaluate prediction for early impairment and longitudinal cognitive change. The optimal 10-fold cross-validation accuracy was 93.07%, compared to 91.83% without age detrending. In the validation dataset, the classifier for AD obtained an accuracy of 84.85% (56/66), sensitivity of 85.36% (35/41) and specificity of 84% (21/25). Classification accuracy was improved when using the lifespan sample as opposed to the classification sample. Importantly, we observed cross-sectional greater AD specific biomarkers, as well as faster cognitive decline in MCI who were classified as more ‘AD-like’ (MCI-AD), and these effects were pronounced in individuals who were late MCI. The top five contributive features were volumes of left hippocampus, right hippocampus, left amygdala, the thickness of left and right middle temporal & parahippocampus gyrus. Linear detrending for age in SVM for combined structural features resulted in good performance for recognition of AD and AD-specific biomarkers, as well as prediction of MCI progression. Such procedures may be used in future work to enhance prediction in samples with atypical age distributions. Elsevier 2020-08-19 /pmc/articles/PMC7476071/ /pubmed/32871388 http://dx.doi.org/10.1016/j.nicl.2020.102387 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regular Article
Li, Binyin
Zhang, Miao
Riphagen, Joost
Morrison Yochim, Kathryn
Li, Biao
Liu, Jun
Salat, David H.
Prediction of clinical and biomarker conformed Alzheimer’s disease and mild cognitive impairment from multi-feature brain structural MRI using age-correction from a large independent lifespan sample
title Prediction of clinical and biomarker conformed Alzheimer’s disease and mild cognitive impairment from multi-feature brain structural MRI using age-correction from a large independent lifespan sample
title_full Prediction of clinical and biomarker conformed Alzheimer’s disease and mild cognitive impairment from multi-feature brain structural MRI using age-correction from a large independent lifespan sample
title_fullStr Prediction of clinical and biomarker conformed Alzheimer’s disease and mild cognitive impairment from multi-feature brain structural MRI using age-correction from a large independent lifespan sample
title_full_unstemmed Prediction of clinical and biomarker conformed Alzheimer’s disease and mild cognitive impairment from multi-feature brain structural MRI using age-correction from a large independent lifespan sample
title_short Prediction of clinical and biomarker conformed Alzheimer’s disease and mild cognitive impairment from multi-feature brain structural MRI using age-correction from a large independent lifespan sample
title_sort prediction of clinical and biomarker conformed alzheimer’s disease and mild cognitive impairment from multi-feature brain structural mri using age-correction from a large independent lifespan sample
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476071/
https://www.ncbi.nlm.nih.gov/pubmed/32871388
http://dx.doi.org/10.1016/j.nicl.2020.102387
work_keys_str_mv AT libinyin predictionofclinicalandbiomarkerconformedalzheimersdiseaseandmildcognitiveimpairmentfrommultifeaturebrainstructuralmriusingagecorrectionfromalargeindependentlifespansample
AT zhangmiao predictionofclinicalandbiomarkerconformedalzheimersdiseaseandmildcognitiveimpairmentfrommultifeaturebrainstructuralmriusingagecorrectionfromalargeindependentlifespansample
AT riphagenjoost predictionofclinicalandbiomarkerconformedalzheimersdiseaseandmildcognitiveimpairmentfrommultifeaturebrainstructuralmriusingagecorrectionfromalargeindependentlifespansample
AT morrisonyochimkathryn predictionofclinicalandbiomarkerconformedalzheimersdiseaseandmildcognitiveimpairmentfrommultifeaturebrainstructuralmriusingagecorrectionfromalargeindependentlifespansample
AT libiao predictionofclinicalandbiomarkerconformedalzheimersdiseaseandmildcognitiveimpairmentfrommultifeaturebrainstructuralmriusingagecorrectionfromalargeindependentlifespansample
AT liujun predictionofclinicalandbiomarkerconformedalzheimersdiseaseandmildcognitiveimpairmentfrommultifeaturebrainstructuralmriusingagecorrectionfromalargeindependentlifespansample
AT salatdavidh predictionofclinicalandbiomarkerconformedalzheimersdiseaseandmildcognitiveimpairmentfrommultifeaturebrainstructuralmriusingagecorrectionfromalargeindependentlifespansample
AT predictionofclinicalandbiomarkerconformedalzheimersdiseaseandmildcognitiveimpairmentfrommultifeaturebrainstructuralmriusingagecorrectionfromalargeindependentlifespansample